AGY Panoramica delle azioni Allergy Therapeutics plc, società commerciale di biotecnologie, si concentra sulla diagnosi e sul trattamento dei disturbi allergici. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Allergy Therapeutics plc Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Allergy Therapeutics Prezzi storici delle azioni Prezzo attuale dell'azione UK£0.077 Massimo di 52 settimane UK£0.08 Minimo di 52 settimane UK£0.018 Beta 1.34 Variazione di 1 mese 20.31% Variazione a 3 mesi 54.00% Variazione di 1 anno n/a Variazione a 3 anni -67.58% Variazione a 5 anni -31.56% Variazione dall'IPO -89.66%
Notizie e aggiornamenti recenti Vedi altri aggiornamenti
Less than half of directors are independent Nov 28
Allergy Therapeutics plc Submits Marketing Authorisation Application for Grass MATA MPL Nov 26
Allergy Therapeutics plc, Annual General Meeting, Dec 16, 2024 Nov 22
Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward Nov 09
Full year 2024 earnings: EPS exceeds analyst expectations Nov 07
New minor risk - Financial data availability Oct 13
Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet Sep 12
New major risk - Share price stability Aug 14
Allergy Therapeutics plc Provides Revenue Guidance for the Second Half and Year Ended 30 June 2024 Jul 23
Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee Jun 27
Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up May 21
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL May 08
Less than half of directors are independent Apr 10
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director Apr 03
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024 Mar 29
First half 2024 earnings released: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023) Mar 29
New minor risk - Financial data availability Mar 17
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors Mar 12
Allergy Therapeutics plc, Annual General Meeting, Mar 08, 2024 Feb 10
Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement Dec 18
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL Dec 13
Allergy Therapeutics plc Announces Interim Top Line Results from its Pivotal G306 Phase III Trial of Grass MATA MPL Nov 14
New major risk - Revenue and earnings growth Oct 31 Allergy Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.891025 million. Oct 14
New major risk - Shareholder dilution Oct 13
Full year 2023 earnings: EPS and revenues miss analyst expectations Sep 28
Allergy Therapeutics plc Announces the Completion of Dosing of Healthy Volunteers in the First Two Cohorts in the Phase I Protect Trial of Its Novel Virus-Like Particle (Vlp)-Based Peanut Allergy Vaccine Candidate Sep 26
Allergy Therapeutics plc Announces Executive Changes Jul 11
First half 2023 earnings: EPS misses analyst expectations Jun 20
Allergy Therapeutics plc Provides Sales Guidance for the Second Half Year to 30 June 2023 and Full Year to 30 June 2024 Jun 20
Less than half of directors are independent Jun 19
Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended 31 December 2022 Jan 20
Allergy Therapeutics plc, Annual General Meeting, Feb 07, 2023 Jan 14
Allergy Therapeutics Announces Resignation of Scott Leinenweber as Non-Executive Director Dec 28
Allergy Therapeutics Announces Key Updates on Grass MATA MPL and VLP Peanut Clinical Programmes Dec 09
Allergy Therapeutics plc Announces Board Appointments Dec 07
Allergy Therapeutics plc Appoints Martin Hopcroft as Interim CFO Nov 21 Allergy Therapeutics plc Resumes UK Manufacturing Production Allergy Therapeutics plc announced that it has received £17 million in funding from Southern Fox Investments Limited Oct 19
Consensus forecasts updated Oct 06 Allergy Therapeutics plc announced that it expects to receive £10 million in funding from Southern Fox Investments Ltd. and other investor Oct 01
Full year 2022 earnings: EPS and revenues miss analyst expectations Sep 30
Allergy Therapeutics plc, Annual General Meeting, Oct 17, 2022 Sep 30
Price target increased to UK£0.67 Jul 27 Allergy Therapeutics plc Provides Revenue Guidance for the Year Ended 30 June 2022 Allergy Therapeutics plc Announces Resignation of Nick Wykeman to Its Board Director, Effective from November 30, 2022
Price target increased to UK£0.59 Apr 27
Less than half of directors are independent Apr 27
Allergy Therapeutics Shares Data at WAO-BSACI Apr 26
First half 2022 earnings: EPS exceeds analyst expectations Mar 05
Allergy Therapeutics plc Announces the Presentation of Positive New Data from Its Two Lead Immunotherapy Programmes At the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting Held in Phoenix, Arizona Mar 03
FDA Clears Allergy Therapeutics Investigational New Drug Application for Its Novel Virus-Like Particle (VLP )-Based Peanut Allergy Vaccine Candidate Jan 26
Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended December 31, 2021 Jan 13
Senior Independent Director Stephen Smith has left the company Nov 29
Senior Independent Director Stephen Smith has left the company Nov 29
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26 Rendimenti per gli azionisti AGY GB Pharmaceuticals GB Mercato 7D 2.1% 4.1% 4.1% 1Y n/a 0.8% 10.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: Dati insufficienti per determinare come si è comportato AGY rispetto al settore UK Pharmaceuticals.
Rendimento vs Mercato: Dati insufficienti per determinare la performance di AGY rispetto al mercato UK.
Volatilità dei prezzi Is AGY's price volatile compared to industry and market? AGY volatility AGY Average Weekly Movement 6.7% Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in GB Market 11.2% 10% least volatile stocks in GB Market 2.7%
Prezzo delle azioni stabile: AGY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato UK.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di AGY è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Allergy Therapeutics plc, società di biotecnologie commerciali, si concentra sulla diagnosi e sul trattamento dei disturbi allergici. L'azienda vende immunoterapie iniettabili e sublinguali specifiche per gli allergeni e offre il trattamento delle allergie legate al polline, in particolare a graminacee, erbacce e alberi, oltre a prodotti diagnostici. I suoi prodotti comprendono Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics e Acarovac Plus.
Mostra di più Allergy Therapeutics plc Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Allergy Therapeutics con la sua capitalizzazione di mercato? AGY statistiche fondamentali Capitalizzazione di mercato UK£367.77m Guadagni(TTM ) -UK£40.22m Ricavi(TTM ) UK£55.20m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) AGY Conto economico (TTM ) Ricavi UK£55.20m Costo del fatturato UK£25.46m Profitto lordo UK£29.74m Altre spese UK£69.95m Guadagni -UK£40.22m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.0084 Margine lordo 53.87% Margine di profitto netto -72.86% Rapporto debito/patrimonio netto 622.8%
Come si è comportato AGY nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/21 05:40 Prezzo dell'azione a fine giornata 2025/01/21 00:00 Guadagni 2024/06/30 Guadagni annuali 2024/06/30
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Allergy Therapeutics plc è coperta da 7 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Adam McCarter Cavendish Gary Waanders Nomura Code Securities Limited Paul Cuddon Numis Securities Ltd.
Mostra 4 altri analisti 
